NCT06719024View on ClinicalTrials.gov

Topical Ruxolitinib for Face and Neck Vitiligo of Adult Chinese Patients Refractory to Topical Tacrolimus

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 29, 2024

Primary Completion Date

June 16, 2025

Study Completion Date

January 30, 2026

Conditions
Vitiligo
Interventions
DRUG

Ruxolitinib Cream 1.5%

a thin layer of the assigned topical to the selected lesions twice daily, maintaining at least an 8-hour interval between applications

DRUG

Aqueous cream

a thin layer of the assigned topical to the selected lesions twice daily, maintaining at least an 8-hour interval between applications

Trial Locations (1)

Unknown

RECRUITING

Queen Mary Hospital, Hospital Authority, Hong Kong

All Listed Sponsors
lead

Hospital Authority, Hong Kong

OTHER_GOV